Docosahexaenoic acid in combination with celecoxib modulates HSP70 and p53 proteins in prostate cancer cells
- 18 July 2006
- journal article
- retracted article
- Published by Wiley in International Journal of Cancer
- Vol. 119 (7) , 1586-1598
- https://doi.org/10.1002/ijc.22031
Abstract
The role of cyclooxygenase‐2 (COX‐2) and the mechanism by which it influences the development and behavior of prostate cancer is unclear. Selective COX‐2 inhibitors may be effective against prostate cancer via COX‐2‐independent mechanisms. But administration of high doses of COX‐2 inhibitors over longer period of time may not be devoid of side effects. There is increasing interest in using COX‐2 inhibitors in combination with other chemopreventive agents to overcome the issue of toxicity. However, the molecular mechanisms underlying their combined actions are not well understood. Therefore, the present study was designed to determine the effects of low doses of docosahexaenoic acid (DHA) in combination with celecoxib on the molecular targets at the proteins level in rat prostate cancer cells. Two‐dimensional gel electrophoresis, in combination with mass spectrometry analysis, was used for protein identification. Western blot analysis confirmed the proteins identified. Paraffin‐embedded tissue sections from the rat prostate tumor were used to detect base level expression of heat shock protein 70 (HSP70) and p53. The rate of cancer cell growth was inhibited more effectively (p < 0.01) by DHA in combination with celecoxib at lower doses (2.5 μM each). A total number of twelve proteins were differentially expressed by the combined action of DHA and celecoxib at low doses. It was interesting to note that these agents activated both HSP70 and p53 proteins. Activation of HSP70 by the combined actions of DHA and celecoxib in the presence of wild‐type p53 reveals a unique COX‐2 independent mode of action against prostate cancer.Keywords
This publication has 59 references indexed in Scilit:
- Interaction of Calcium Supplementation and Nonsteroidal Anti-inflammatory Drugs and the Risk of Colorectal AdenomasCancer Epidemiology, Biomarkers & Prevention, 2005
- Resistance of prostate cancer cell lines to COX-2 inhibitor treatmentBiochemical and Biophysical Research Communications, 2005
- Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma PreventionNew England Journal of Medicine, 2005
- Celecoxib Inhibits Prostate Cancer Growth: Evidence of a Cyclooxygenase-2-Independent MechanismClinical Cancer Research, 2005
- Regression of Mouse Prostatic Intraepithelial Neoplasia by Nonsteroidal Anti-inflammatory Drugs in the Transgenic Adenocarcinoma Mouse Prostate ModelClinical Cancer Research, 2004
- Resveratrol-induced cell growth inhibition and apoptosis is associated with modulation of phosphoglycerate mutase B in human prostate cancer cells: two-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis and mass spectrometry evaluationCancer Detection Prevention, 2004
- p53 Inhibitor Pifithrin α Can Suppress Heat Shock and Glucocorticoid Signaling PathwaysJournal of Biological Chemistry, 2003
- Multiple pathways of prostate carcinogenesis analyzed by using cultured cells isolated from rats treated withN-methyl-N-nitrosourea and testosteroneMolecular Carcinogenesis, 1999
- Induction ofHSP70 gene expression by modulation of Ca+2 ion and cellular p53 protein by curcumin in colorectal carcinoma cellsMolecular Carcinogenesis, 1996
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976